Rigin

Rigin (Palmitoyl Tetrapeptide-7) is a synthetic cosmetic peptide developed to address skin inflammation and age-related matrix degradation. It is proposed to suppress interleukin-6 (IL-6), a cytokine associated with chronic low-grade skin inflammation that accelerates extracellular matrix breakdown. Evidence for rigin is primarily derived from manufacturer-sponsored in vitro and ex vivo cosmetic research; no independent peer-reviewed clinical trials have been identified in indexed biomedical literature. Rigin is a cosmetic ingredient developed by Sederma/Croda; its evidence base consists of manufacturer-sponsored studies only and it has not been evaluated by regulatory agencies for any medicinal claim. Rigin and Matrixyl 3000 Rigin (Palmitoyl Tetrapeptide-7, Pal-GQPR) is one of two peptide actives in Sederma's Matrixyl 3000 formulation — the other being Matrixyl (palmitoyl pentapeptide-4, Pal-KTTKS). In the Matrixyl 3000 combination, the two peptides are proposed to address complementary aspects of skin aging: Matrixyl (Pal-KTTKS) stimulates new collagen I and III synthesis via TGF-β signaling; Rigin (Pal-GQPR) suppresses IL-6-mediated matrix degradation, reducing the rate at which newly synthesised collagen is broken down. The combination therefore targets both the anabolic (synthesis) and anti-catabolic (degradation prevention) sides of collagen matrix maintenance. This mechanistic pairing is the basis for the "3000" formulation's improved efficacy claims relative to the original single-peptide Matrixyl. In cosmetic formulations, Rigin is listed under its INCI name (Palmitoyl Tetrapeptide-7) and appears alongside palmitoyl pentapeptide-4 in products marketed as containing Matrixyl 3000. Typical concentration in the final product is in the range of 4–8% of the Sederma Matrixyl 3000 concentrate, which itself contains the peptides at a defined dilution. Rigin is a topical cosmetic ingredient — it has no injectable or clinical pharmaceutical application and does not require a prescription in any jurisdiction.